Polarean is a leader in the field of hyperpolarization science and aspires to revolutionize pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung function, diagnose disease, characterize disease progression, and monitor response to treatment. On December 23, 2022, the FDA granted approval for Polarean’s first drug device combination product, XENOVIEWTM (xenon Xe 129 hyperpolarized) the first and only hyperpolarized MRI contrast agent to be approved in the United States.
